SUCCOUR MRI SUB-STUDY
To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.
To be considered for this study you must meet the following criteria:
- Be about to undergo treatment (or received ≤3 cycles) of anthracycline-containing chemotherapy AND ≥1 of the following:
- a. Trastuzumab in breast cancer with the HER2 mutation OR
- b. Tyrosine kinase inhibitors OR
- c. Cumulative anthracycline dose >450 mg/m2 OR
- d. Chest radiotherapy (left-sided) OR
- e. Prior treatment with anthracycline or chest-directed radiotherapy for cancer OR
- f. Increased risk of heart failure (age ≥65 years old, type II diabetes, hypertension, prior cardiac injury, e.g. heart attack)
- g. Patients who have completed anthracycline treatment but will continue to be treated with other cardiotoxic treatments such as trastuzumab, tyrosine kinase inhibitors or left-chest radiotherapy during the course of surveillance
Your participation in this study would be for approximately 1 year.
You will need to attend the clinic for an initial assessment, including medical history and physical examination, blood tests, ECG, echocardiogram, cardiac MRI and completing questionnaires regarding physical symptoms and quality of life.
You will then be reviewed every 3 months, up to 12 months. (i.e. 5 visits in total, including baseline visit). Tests performed at review would include an echocardiogram and completing questionnaires regarding physical symptoms and quality of life.
You will be reimbursed for travel and study related expenses.